Suppr超能文献

造血干细胞植入:非人灵长类动物骨髓内注射与静脉注射的直接比较

Hematopoietic stem cell engraftment: a direct comparison between intramarrow and intravenous injection in nonhuman primates.

作者信息

Jung Chul Won, Beard Brian C, Morris Julia C, Neff Tobias, Beebe Katherine, Storer Barry E, Kiem Hans-Peter

机构信息

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.

出版信息

Exp Hematol. 2007 Jul;35(7):1132-9. doi: 10.1016/j.exphem.2007.04.004.

Abstract

OBJECTIVE

Recent studies in the mouse model have shown improved engraftment of repopulating cells when cells were administered by intramarrow (IM) vs intravenous (IV) injection. Here we wished to determine if IM injection was feasible and would result in improved engraftment in a clinically relevant large animal model.

MATERIALS AND METHODS

We used a competitive repopulation assay to directly compare IM vs IV injection in four baboons. CD34+ autologous bone marrow cells were split into two equal fractions and transduced with either green fluorescent protein (GFP) or yellow fluorescent protein (YFP). Gene-marked cells were infused by IM or IV administration after myeloablative irradiation.

RESULTS

Peripheral blood granulocyte marking peaked at 2 to 3 weeks after transplantation and decreased thereafter before stabilizing. In all animals, marking levels of IM-injected cells (GFP) were lower than those of IV-injected cells (YFP) early after transplantation. However, in two of the four monkeys, GFP marking steadily increased after 2 months resulting in higher marking levels from IM-injected cells. In one animal, this trend sustained up to the last follow-up at 1 year after transplantation, with marking levels of 63.4% and 9.7% from IM- and IV-injected cells, respectively. Transplantation of both IM- and IV-injected CD34+ cells resulted in polyclonal multilineage engraftment.

CONCLUSION

Our data show efficient gene marking after IM injection and suggest a different engraftment profile for IM- vs IV-injected repopulating cells.

摘要

目的

最近在小鼠模型中的研究表明,与静脉内(IV)注射相比,通过骨髓内(IM)注射细胞时,再增殖细胞的植入情况有所改善。在此,我们希望确定IM注射在临床相关的大型动物模型中是否可行,以及是否会导致更好的植入效果。

材料与方法

我们使用竞争性再增殖试验直接比较4只狒狒的IM注射与IV注射。将CD34+自体骨髓细胞分成两个相等的部分,并用绿色荧光蛋白(GFP)或黄色荧光蛋白(YFP)进行转导。在清髓性照射后,通过IM或IV给药注入基因标记的细胞。

结果

外周血粒细胞标记在移植后2至3周达到峰值,此后下降,然后趋于稳定。在所有动物中,移植后早期,IM注射细胞(GFP)的标记水平低于IV注射细胞(YFP)。然而,在4只猴子中的2只中,2个月后GFP标记稳步增加,导致IM注射细胞的标记水平更高。在1只动物中,这种趋势一直持续到移植后1年的最后一次随访,IM和IV注射细胞的标记水平分别为63.4%和9.7%。IM和IV注射的CD34+细胞移植均导致多克隆多谱系植入。

结论

我们的数据显示IM注射后基因标记有效,并表明IM注射与IV注射的再增殖细胞植入情况不同。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验